Ayers et al. revealed that the IFN-γ-related gene profile obtained from baseline tumor tissues was related to an overall better response and PFS in the patients with melanoma, head and neck cancer, and gastric cancer who were treated with pembrolizumab (54). The gene discussed is IFNG; the disease is neoplasm.